Sinopharm Group (1099.HK) rebounds after posting an upbeat 9-month result

Sinopharm Group rebounds after reporting its 9-month result.

Charts (4)

Sinopharm Group (1099), a pharmaceutical company, rose around 5% after the company announced that 9-month net income grew 7.8% on year to 4.96 billion yuan on operating revenue of 327.61 billion yuan, up 4.8%.

Besides, Chinese Media reported that 4 Covid-19 Vaccines of Sinopharm are conducting the Phase III clinical tests in overseas countries.

Technically, the stock posted a rebound and broke above a declining channel. Currently, the prices stand above its 20-day moving average. The relative strength index also indicates a bullish divergence signal.

The bullish readers could set a support level at HK$16.40, while resistance levels would be HK$19.00 and HK$20.40.


Source: GAIN Capital, TradingView

More from Equities

Disclaimer: GAIN Capital UK Limited (trading as "Forex.com") is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, Forex.com does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by Forex.com or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although Forex.com is not specifically prevented from dealing before providing this material, Forex.com does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.